September 29, 2016


CMIC Co., Ltd., a consolidated subsidiary of CMIC HOLDINGS Co., Ltd., has announced that the company has established new department called “Regenerative Medicine of Clinical Research Dept.”, which specializes in clinical trials and research in Regenerative Medicine, effective as of October 1st.

As result of a law amendments* in November 2014, has led to the establishment of practice criteria for clinical trials and an expedited approval system for regenerative medicine. This new legislation will lead to an increase in domestic and foreign customers who are considering the development and launch of regenerative medical products in Japan. The CMIC Group has promoted approaches to the regenerative medicine field by establishing a specialized consulting team for regenerative medicine in May 2015, and built a new facility in July 2016, in preparation for the biological safety studies that will be needed for the development of regenerative medicine. CMIC is further encouraging the spread of regenerative medicine quickly and safely through the establishment of its new department of Regenerative Medicine specialized in clinical trials and research. Also, the company will continually increase in personnel including experts in related oncology and central nerve fields, due to increasing orders.
* The Act on the Safety of Regenerative Medicine and the Act on Pharmaceuticals and Medical Devices


【CMIC Co., Ltd.】
CMIC Co., Ltd. has provided services to promote the efficiency and acceleration of clinical trials as the first CRO in Japan. The CMIC Group today provides comprehensive support services for development, manufacturing, sales, and marketing for the pharmaceutical industry. CMIC Group has developed a unique business model that we call “Pharmaceutical Value Creator (PVC)” based on our abundant accumulation of experience and knowledge as a CRO pioneer. CMIC utilizes PVC to create new value in the healthcare field.

For more information:
CMIC Co., Ltd.:

Press contact:
Corporate Communication Division PR Group
Tel: +81-3-6779-8200 / E-mail: